title: Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study.
abstract: Chronic graft-versus-host disease (GVHD) remains a serious complication after allogeneic hematopoietic stem cell transplantation (HCT). In 2005 the National Institutes of Health (NIH) established new criteria for chronic GVHD based on retrospective data and expert recommendations. We prospectively evaluated the incidence of NIH-defined chronic GVHD and its prognostic impact in 178 consecutive patients. The cumulative incidence of chronic GVHD at 3 years was 64, 48 and 16% for chronic classic GVHD and overlap syndrome. Prior acute GVHD and myeloablative conditioning were significantly associated with increased risk of chronic GVHD. Three-year survival (overall survival (OS)) for late-acute GVHD, chronic classic and overlap chronic GVHD when assigned on day 100 were 69, 83 and 73%. OS was significantly worse for patients with platelet counts below 100 g/l at onset of chronic GVHD (35% versus 86%, P<0.0001) and progressive as compared with de novo and quiescent onset of chronic GVHD (54.5% versus 89.5% versus 84%, P = 0.022 and 0.001). Peak severity of chronic GVHD had no impact on non-relapse mortality (NRM) and OS. Recurrent acute GVHD, platelet counts below 100 g/l at diagnosis of chronic GVHD, progressive onset of chronic GVHD and advanced disease stage prior to HCT were significantly associated with increased NRM. This prospective analysis provides for the first-time data on the incidence rates of NIH-defined chronic GVHD categories and identified risk factors for the occurrence of chronic GVHD. A prognostic value of thrombocytopenia and progressive onset type of chronic GVHD for survival after HCT was observed in NIH-defined chronic GVHD.
authors.affiliation: Department of Internal Medicine I, Bone Marrow Transplantation, Medical University of Vienna, Vienna, Austria.
authors.forename: Z
authors.initials: Z
authors.lastname: Kuzmina
authors.forename: S
authors.initials: S
authors.lastname: Eder
authors.forename: A
authors.initials: A
authors.lastname: Böhm
authors.forename: E
authors.initials: E
authors.lastname: Pernicka
authors.forename: L
authors.initials: L
authors.lastname: Vormittag
authors.forename: P
authors.initials: P
authors.lastname: Kalhs
authors.forename: V
authors.initials: V
authors.lastname: Petkov
authors.forename: G
authors.initials: G
authors.lastname: Stary
authors.forename: J
authors.initials: J
authors.lastname: Nepp
authors.forename: R
authors.initials: R
authors.lastname: Knobler
authors.forename: U
authors.initials: U
authors.lastname: Just
authors.forename: K
authors.initials: K
authors.lastname: Krenn
authors.forename: N
authors.initials: N
authors.lastname: Worel
authors.forename: H T
authors.initials: HT
authors.lastname: Greinix
mesh_terms: D000328:Adult; D000368:Aged; D002908:Chronic Disease; D018450:Disease Progression; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000401:mortality*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012307:Risk Factors; D012720:Severity of Illness Index; D013921:Thrombocytopenia / Q000401:mortality*